Effects of a lower versus a higher oxygenation target in intensive care unit patients with chronic obstructive pulmonary disease and acute hypoxaemic respiratory failure: a subgroup analysis of a randomised clinical trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 464 KB, PDF-dokument

  • Maria B. Nielsen
  • Thomas L. Klitgaard
  • Ulla M. Weinreich
  • Frederik M. Nielsen
  • Perner, Anders
  • Olav L. Schjørring
  • Bodil S. Rasmussen
Background
Oxygen supplementation is ubiquitous in intensive care unit (ICU) patients with chronic obstructive pulmonary disease (COPD) and acute hypoxaemia, but the optimal oxygenation target has not been established.

Methods
This was a pre-planned subgroup analysis of the Handling Oxygenation Targets in the ICU (HOT-ICU) trial, which allocated patients with acute hypoxaemia to a lower oxygenation target (partial pressure of arterial oxygen [Pao2] of 8 kPa) vs a higher target (Pao2 of 12 kPa) during ICU admission, for up to 90 days; the allocation was stratified for presence or absence of COPD. Here, we report key outcomes for patients with COPD.

Results
The HOT-ICU trial enrolled 2928 patients of whom 563 had COPD; 277 were allocated to the lower and 286 to the higher oxygenation group. After allocation, the median Pao2 was 9.1 kPa (inter-quartile range 8.7–9.9) in the lower group vs 12.1 kPa (11.2–12.9) in the higher group. Data for arterial carbon dioxide (Paco2) were available for 497 patients (88%) with no between-group difference in time-weighted average; median Paco2 6.0 kPa (5.2–7.2) in the lower group vs 6.2 kPa (5.4–7.3) in the higher group. At 90 days, 122/277 patients (44%) in the lower oxygenation group had died vs 132/285 patients (46%) in the higher (relative risk 0.98; 95% confidence interval 0.82–1.17; P=0.67). No statistically significant differences were found in any secondary outcome.

Conclusions
In ICU patients with COPD and acute hypoxaemia, a lower vs a higher oxygenation target did not reduce mortality. There were no between-group differences in Paco2 or in secondary outcomes.
OriginalsprogEngelsk
Artikelnummer100281
TidsskriftBJA Open
Vol/bind10
Antal sider9
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
The HOT-ICU trial was funded by a grant from Innovation Fund Denmark (4108-00011A) and supported by Aalborg University Hospital, the Regions of Denmark (EMN-2017-00901 and EMN-2019-01055), the Obel Family Foundation (25457), the Danish Society of Anaesthesiology and Intensive Care Medicine, and the Intensive Care Symposium Hindsgavl. No additional funding was provided for this sub-study. Funders of this study had no role in the design, collection, analysis, interpretation of data, or writing of this report.

Funding Information:
The Department of Intensive Care at Rigshospitalet has received funding for other projects from the Novo Nordisk Foundation, Pfizer, Sygeforsikringen \u2018danmark\u2019 and Fresenius Kabi and does contract research for AM Pharma. UMW has received fees, including transportation reimbursement for: Congress participation: Orion Pharma; Advisory boards: TEVA, Astra Zeneca, Chiesi and Novartis; Speaker\u2019s fees: Astra Zeneca, Chiesi, Novartis, Boehringer Ingelheim, GSK, Orion Pharma, Fisher&Paykel Healthcare and ResMed; Writer\u2019s fee: Astra Zeneca; Pharma-initiated research: Astra Zeneca, GSK, Novartis, Ins-Med, Sanofi, Novartis, Boehringer Ingelheim and Genetech; Research grant: Fisher&Paykel Healthcare and Liita Healthcare.

Publisher Copyright:
© 2024 The Authors

ID: 391210258